Table 1.
BAF binding partners | Functions | Assays to analyze interaction with BAF1,2 | References |
---|---|---|---|
LEM-domain proteins | |||
Emerin | Mitosis, integral component of nuclear inner membrane | Blot overlay assay, co-IP, microtiter binding assay, FRET, NMR, co-localization by IF | [11,14,21,38,40,67] |
LAP2α | Mitosis, transcriptional regulator | Native gel shift assay, NMR, in vitro binding assay, co-IP, co-localization by IF | [13,15,77] |
LAP2β | Mitosis, integral component of nuclear inner membrane, transcriptional repressor | Y2H, native gel shift assay, in vitro binding assay, NMR | [9,13,15] |
MAN1 | Integral component of nuclear inner membrane | Microtiter binding assay | [10] |
Lamin A | Mitosis, structural component of the nuclear envelope, signaling | Microtiter binding assay, FRET, AP-MS** | [40,67,68] |
Prelamin A | Precursor form of lamin A | Co-IP, co-localization by IF | [28,32] |
Progerin | Truncated form of farnesylated prelamin A | Co-IP, co-localization by IF | [28] |
Lamin B | Structural component of the nuclear envelope | Subcellular co-fractionation | [78] |
LEM2 | Integral component of nuclear inner membrane | Co-localization by IF | [79] |
Ankle1/Lem3 | DNA damage response | In vitro pulldown assay | [73] |
Nemp1 | Inner membrane nuclear protein in Xenopus, neural development | GST-pulldown assay, co-localization by IF | [80] |
Transcriptional regulators | |||
Crx * | Homeodomain transcription activator, organ morphogenesis | Y2H, in vitro pulldown, co-IP, IF, NMR | [65,66] |
LAP2ζ | Regulator of LAP2β-mediated transcriptional repressor | Co-IP, co-localization by IF | [27] |
Requiem | Transcription factor in myeloid cells, apoptosis | Co-IP, AP-MS | [68] |
Sox2 | Embryonic stem cell differentiation | AP-MS (MudPIT) | [64] |
Histones and histone regulators | |||
H1.1 | Nucleosome | Blot overlay assay, microtiter binding assay, GST-pulldown | [70] |
H3 | Nucleosome | Blot overlay assay, microtiter binding assay, GST-pulldown, AP-MS | [68,70] |
H4 | Nucleosome | In vitro pulldown assay | [69] |
RBBP4 | Histone chaperone | Co-IP, AP-MS | [68] |
SET/I2PP2A | Mitosis, nucleosome assembly, gene expression | Co-IP, AP-MS | [68,69] |
G9A | Histone methylation | Co-IP, AP-MS | [69] |
DNA damage repair proteins | |||
PARP1 | DNA damage response, gene expression | Co-IP, AP-MS | [68] |
DDB1, DDB2 | DNA damage response, protein degradation | Co-IP, AP-MS | [68] |
CUL4 | Protein ubiquitination | Co-IP, AP-MS | [68] |
Kinases | |||
VRK1 | Mitosis, histone phosphorylation, protein phosphorylation | In vitro kinase assay | [23,24,39,46] |
VRK2 | Protein phosphorylation, signaling | In vitro kinase assay | [23,46] |
B1 | Vaccinia kinase required for viral DNA replication and gene expression | In vitro kinase assay | [23,29] |
Phosphatases | |||
PP2A | Mitosis, protein dephosphorylation, gene expression | In vitro phosphatase assay | [35] |
PP4 | Protein dephosphorylation, DNA damage response | siRNA depletion of PP4 | [36] |
Others | |||
BAF-L | Potential regulator of BAF DNA binding | In vitro pulldown assay | [8] |
Interaction with BAF is mediated by DNA
Bold letters indicate assays performed using purified proteins suggesting direct interaction with BAF
Underlined letters indicate assays performed using sequence common to all isoforms of LAP2
Abbreviations: Co-IP (co-immunoprecipitation), Y2H (yeast two hybrid), IF (immunofluorescence), NMR (nuclear magnetic resonance), FRET (fluorescence resonance energy transfer), AP-MS (affinity purification followed by mass spectrometry).